Key Highlights: Implications: This means Skymap Pharma is set to take over IMPCL as the government exits ownership, turning a long-running public-sector Ayurvedic and Unani manuf...
Key Highlights: Implications: Align’s new Hyderabad plant is a big capacity and margin move, not just a footprint expansion. It should make the company more resilient on supply, ...
Key Highlights: Implications: GTBL’s MicroBiopharm acquisition is a strategic move to become a more integrated, higher-value pharma services and ingredients player. The mai...
Key Highlights: Implications: The merger gives HAB Pharma a bigger scale story: a cleaner corporate structure, more manufacturing capacity, and a stronger platform to sell specialty products in more ...
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: Vyome is buying its way into a large, fast‑growing immunology market with next‑generation, more selective JAK inhibitors, without overextending its balan...
Key Highlights: Implications: Triple Hair is turning TH07 into a genuinely global late‑stage asset in male pattern hair loss by running synchronized Phase III trials in Canada and In...
Key Highlights: Implications: Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers...
Key Highlights Implications: Lormalzi gives Lilly an early foothold in India’s tiny but fast‑growing market for disease‑modifying Alzheimer’s drugs, while it test...
Key Highlights: Implications: With legal access to the Charpentier CRISPR/Cas9 patents, Aurigene can now run gene‑editing projects (target validation, disease models, f...